Impact of Diffusion Barriers to Small Cytotoxic Molecules on the Efficacy of Immunotherapy in Breast Cancer

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Das, Hiranmoy ^a   Wang, Zhihui ^b   Niazi, M Khalid Khan ^c   Aggarwal, Reeva ^a   Lu, Jingwei ^a   Kanji, Suman ^a   Das, Manjusri ^a   Joseph, Matthew ^a   Gurcan, Metin ^c   Cristini, Vittorio ^b,d  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d University of New Mexico   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL TRANSPORT; CELLULAR SECRETION; CONTROLLED STUDY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; MATHEMATICAL MODEL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PREDICTION; PROCESS DEVELOPMENT; PROTEIN FUNCTION; TUMOR CELL DESTRUCTION;

ADULT; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL SURVIVAL; DIFFUSION; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; MODELS, BIOLOGICAL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; TREATMENT OUTCOME;

EID: 84876452244     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061398     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Bank I, Book M, Huszar M, Baram Y, Schnirer I, et al. (1993) V delta 2+ gamma delta T lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T cells that infiltrate breast tumors. Clin Immunol Immunopathol 67: 17-24.
3. Watanabe N, Hizuta A, Tanaka N, Orita K, (1995) Localization of T cell receptor (TCR)-gamma delta+T cells into human colorectal cancer: flow cytometric analysis of TCR-gamma delta expression in tumour-infiltrating lymphocytes. Clin Exp Immunol 102: 167-173.
4. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, Amunni G, Villanucci A, et al. (2005) Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 16: 590-596.
5. Rosenberg SA, Yang JC, Restifo NP, (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
6. Alam SM, Clark JS, Leech V, Whitford P, George WD, et al. (1992) T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients. Immunol Lett 31: 279-283.
7. Brenner MB, McLean J, Dialynas DP, Strominger JL, Smith JA, et al. (1986) Identification of a putative second T-cell receptor. Nature 322: 145-149.
8. Shin S, El-Diwany R, Schaffert S, Adams EJ, Garcia KC, et al. (2005) Antigen recognition determinants of gammadelta T cell receptors. Science 308: 252-255.
9. Bukowski JF, Morita CT, Brenner MB, (1999) Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 11: 57-65.
10. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, et al. (1994) Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 264: 267-270.
11. Modlin RL, Pirmez C, Hofman FM, Torigian V, Uyemura K, et al. (1989) Lymphocytes bearing antigen-specific gamma delta T-cell receptors accumulate in human infectious disease lesions. Nature 339: 544-548.
12. Das H, Groh V, Kuijl C, Sugita M, Morita CT, et al. (2001) MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15: 83-93.
13. Wang L, Kamath A, Das H, Li L, Bukowski JF, (2001) Antibacterial effect of human V gamma 2V delta 2 T cells in vivo. J Clin Invest 108: 1349-1357.
14. Wang L, Das H, Kamath A, Bukowski JF, (2001) Human V gamma 2V delta 2 T cells produce IFN-gamma and TNF-alpha with an on/off/on cycling pattern in response to live bacterial products. J Immunol 167: 6195-6201.
15. Macklin P, McDougall S, Anderson AR, Chaplain MA, Cristini V, et al. (2009) Multiscale modelling and nonlinear simulation of vascular tumour growth. J Math Biol 58: 765-798.
16. Owen MR, Alarcon T, Maini PK, Byrne HM, (2009) Angiogenesis and vascular remodelling in normal and cancerous tissues. J Math Biol 58: 689-721.
17. Jackson TL, (2003) Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model. J Theor Biol 220: 201-213.
18. Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, et al. (2009) Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res 69: 4484-4492.
19. Sinek JP, Sanga S, Zheng X, Frieboes HB, Ferrari M, et al. (2009) Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol 58: 485-510.
20. Wang Z, Bordas V, Deisboeck TS (2011) Identification of critical molecular components in a multiscale cancer model based on the integration of Monte Carlo, resampling, and ANOVA. Frontiers in Computational Physiology and Medicine In press.
21. Wang Z, Bordas V, Sagotsky J, Deisboeck TS (2010) Identifying therapeutic targets in a combined EGFR-TGF{beta}R signalling cascade using a multiscale agent-based cancer model. Math Med Biol.
22. Anderson AR, Weaver AM, Cummings PT, Quaranta V, (2006) Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127: 905-915.
23. Frieboes HB, Zheng X, Sun CH, Tromberg B, Gatenby R, et al. (2006) An integrated computational/experimental model of tumor invasion. Cancer Res 66: 1597-1604.
24. Lee HO, Silva AS, Concilio S, Li YS, Slifker M, et al. (2011) Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model. Cancer Res 71: 6327-6337.
25. Wang Z, Birch CM, Sagotsky J, Deisboeck TS, (2009) Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model. Bioinformatics 25: 2389-2396.
26. Lu J, Aggarwal R, Kanji S, Das M, Joseph M, et al. (2011) Human ovarian tumor cells escape gammadelta T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules. PLoS One 6: e23348.
27. Kabelitz D, Wesch D, Pitters E, Zoller M, (2004) Potential of human gammadelta T lymphocytes for immunotherapy of cancer. Int J Cancer 112: 727-732.
28. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, et al. (2007) Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 179: 3332-3341.
29. Bissell MJ, Hines WC, (2011) Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17: 320-329.
30. Cho K, Wang X, Nie S, Chen ZG, Shin DM, (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14: 1310-1316.
31. Bagri A, Berry L, Gunter B, Singh M, Kasman I, et al. (2010) Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 16: 3887-3900.
32. Jain RK, (1999) Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1: 241-263.
33. Ferrarini M, Heltai S, Toninelli E, Sabbadini MG, Pellicciari C, et al. (1995) Daudi lymphoma killing triggers the programmed death of cytotoxic V gamma 9/V delta 2 T lymphocytes. J Immunol 154: 3704-3712.
34. Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB, (1988) A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res 48: 3461-3469.
35. Russell JH, (1995) Activation-induced death of mature T cells in the regulation of immune responses. Curr Opin Immunol 7: 382-388.
36. Mollinedo F, Gajate C, (2006) Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat 9: 51-73.
37. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH, (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-441.
38. Ikeda H, Old LJ, Schreiber RD, (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13: 95-109.
39. Das H, Sugita M, Brenner MB, (2004) Mechanisms of Vdelta1 gammadelta T cell activation by microbial components. J Immunol 172: 6578-6586.
40. Das H, Wang L, Kamath A, Bukowski JF, (2001) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98: 1616-1618.
41. Gurcan M, Boucheron L, Can A, Madabhushi A, Rajpoot N, et al. (2009) Histopathological image analysis: A review. IEEE Reviews in Biomedical Engineering 2: 147-171.
42. Robertson A, (1990) Historical development of CIE recommended color difference equations. Color Research & Application 15: 167-170.
43. Elden L, Berry MW, (2008) Matrix Methods in Data Mining and Pattern Recognition. SIAM review 50: 154.
44. Kapur J, Sahoo PK, Wong A, (1985) A new method for gray-level picture thresholding using the entropy of the histogram. Computer vision, graphics, and image processing 29: 273-285.
45. Arya SK, Lee KC, Dah'alan DB, Daniel, Rahman AR, (2012) Breast tumor cell detection at single cell resolution using an electrochemical impedance technique. Lab Chip 12: 2362-2368.